Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins.

Enkirch T, Kneissl S, Hoyler B, Ungerechts G, Stremmel W, Buchholz CJ, Springfeld C.

Gene Ther. 2013 Jan;20(1):16-23. doi: 10.1038/gt.2011.209. Epub 2012 Jan 5.

PMID:
22218301
2.
3.

Targeted cell entry of lentiviral vectors.

Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ.

Mol Ther. 2008 Aug;16(8):1427-36. doi: 10.1038/mt.2008.128. Epub 2008 Jun 24.

4.

Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies.

Kneissl S, Abel T, Rasbach A, Brynza J, Schneider-Schaulies J, Buchholz CJ.

PLoS One. 2012;7(10):e46667. doi: 10.1371/journal.pone.0046667. Epub 2012 Oct 10.

5.

Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells.

Lévy C, Amirache F, Costa C, Frecha C, Muller CP, Kweder H, Buckland R, Cosset FL, Verhoeyen E.

Mol Ther. 2012 Sep;20(9):1699-712. doi: 10.1038/mt.2012.96. Epub 2012 May 22.

6.

Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins.

Hudacek AW, Navaratnarajah CK, Cattaneo R.

Cancer Gene Ther. 2013 Feb;20(2):109-16. doi: 10.1038/cgt.2012.92. Epub 2013 Jan 11.

7.

A Tupaia paramyxovirus vector system for targeting and transgene expression.

Engeland CE, Bossow S, Hudacek AW, Hoyler B, Förster J, Veinalde R, Jäger D, Cattaneo R, Ungerechts G, Springfeld C.

J Gen Virol. 2017 Sep;98(9):2248-2257. doi: 10.1099/jgv.0.000887. Epub 2017 Sep 8.

PMID:
28809150
9.

Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response.

Uhlig KM, Schülke S, Scheuplein VA, Malczyk AH, Reusch J, Kugelmann S, Muth A, Koch V, Hutzler S, Bodmer BS, Schambach A, Buchholz CJ, Waibler Z, Scheurer S, Mühlebach MD.

J Virol. 2015 Sep;89(17):9044-60. doi: 10.1128/JVI.00844-15. Epub 2015 Jun 17.

10.

Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors.

Frecha C, Lévy C, Costa C, Nègre D, Amirache F, Buckland R, Russell SJ, Cosset FL, Verhoeyen E.

J Virol. 2011 Jun;85(12):5975-85. doi: 10.1128/JVI.00324-11. Epub 2011 Mar 30.

11.
12.

Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins.

Frecha C, Costa C, Nègre D, Gauthier E, Russell SJ, Cosset FL, Verhoeyen E.

Blood. 2008 Dec 15;112(13):4843-52. doi: 10.1182/blood-2008-05-155945. Epub 2008 Sep 23.

14.

Lentiviral vectors pseudotyped with envelope glycoproteins derived from human parainfluenza virus type 3.

Jung C, Grzybowski BN, Tong S, Cheng L, Compans RW, Le Doux JM.

Biotechnol Prog. 2004 Nov-Dec;20(6):1810-6.

PMID:
15575716
15.
17.

Efficient transduction of neurons using Ross River glycoprotein-pseudotyped lentiviral vectors.

Jakobsson J, Nielsen TT, Staflin K, Georgievska B, Lundberg C.

Gene Ther. 2006 Jun;13(12):966-73. Epub 2006 Mar 2.

PMID:
16511527
19.

CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes.

Kneissl S, Zhou Q, Schwenkert M, Cosset FL, Verhoeyen E, Buchholz CJ.

PLoS One. 2013 Nov 11;8(11):e79047. doi: 10.1371/journal.pone.0079047. eCollection 2013.

20.

Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus.

Zhang XY, Kutner RH, Bialkowska A, Marino MP, Klimstra WB, Reiser J.

Retrovirology. 2010 Jan 25;7:3. doi: 10.1186/1742-4690-7-3.

Supplemental Content

Support Center